.Planet Health Association. Obesity and obese. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Ailment Danger Variable Cooperation. Worldwide styles in undersized as well as weight problems coming from 1990 to 2022: a pooled evaluation of 3663 population-representative researches with 222 thousand kids, adolescents, and adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Worldwide Burden Health Condition Partners. Global, local, as well as national concern of diabetes from 1990 to 2021, with projections of occurrence to 2050: a step-by-step evaluation for the International Worry of Condition Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google.com Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Planet Kidney Time Steering Committee. Excessive weight and also renal condition: hidden repercussions of the prevalent. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
A methodical customer review as well as meta-analysis proposes excessive weight predicts beginning of chronic kidney health condition in the overall populace. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google Scholaru00c2.Jiang, Z. et al. Being overweight as well as persistent renal disease.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., will Carmo, J. M., da Silva, A.
A., Wang, Z. & Hall, M. E.
Excessive weight, kidney dysfunction as well as high blood pressure: mechanistic hyperlinks. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Renal Ailment: Improving Worldwide End Results CKD Work Team.
KDIGO 2024 Scientific Process Guideline for the evaluation and also administration of chronic kidney disease. Kidney Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Kidney Ailment: Improving International Results Diabetic Issues The Office Group. KDIGO 2022 Medical Process Guideline for diabetic issues monitoring in constant renal illness. Renal Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et cetera.
Early improvement in albuminuria with canagliflozin anticipates kidney as well as heart end results: a message hoc review from the support test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.de Zeeuw, D. et cetera. Proteinuria, an aim at for renoprotection in people along with style 2 diabetic person nephropathy: lessons coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et al. Is actually a decline in albuminuria linked with kidney as well as cardiovascular security?
An article hoc review of the ALTITUDE trial. Diabetes Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic kidney condition: a testimonial of their renal as well as heart security. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et cetera. GLP-1 and also the kidney: coming from anatomy to pharmacology as well as outcomes in diabetes.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Marso, S. P.
et al. Semaglutide and cardio outcomes in individuals with kind 2 diabetes. N.
Engl. J. Medication.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide and also cardiovascular outcomes in being overweight without diabetes. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et al.
Results of semaglutide on chronic kidney illness in patients along with style 2 diabetic issues. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Colhoun, H. M. et cetera.
Long-term kidney end results of semaglutide in weight problems as well as cardiovascular disease in the SELECT trial. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Results of semaglutide on albuminuria and renal function in individuals along with overweight or even weight problems with or even without style 2 diabetic issues: exploratory analysis coming from the action 1, 2, and 3 trials.
Diabetic issues Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Medicine Man, A. M.
et cetera. Impact of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal results in clients along with kind 2 diabetes mellitus: pooled evaluation of SUSTAIN 6 and forerunner. Blood circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et cetera.
Effect of semaglutide on renal function throughout various amounts of standard HbA1c, blood pressure, body system weight as well as albuminuria in SUSTAIN 6 and also leader 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus blood insulin glargine in people with style 2 diabetes mellitus as well as moderate-to-severe severe kidney disease (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetes Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Adjustment in albuminuria as a surrogate endpoint for progress of kidney disease: a meta-analysis of procedure effects in randomised clinical tests. Lancet Diabetic Issues Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et al. Results of semaglutide along with and without concomitant SGLT2 inhibitor usage in participants along with style 2 diabetes and persistent renal disease in the circulation trial. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et al. Cardiovascular, renal as well as safety and security end results with GLP-1 receptor agonists alone and in mix along with SGLT2 preventions in type 2 diabetic issues: a step-by-step evaluation and meta-analysis.
Flow https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et al. Efficiency and also protection of SGLT2 inhibitors along with as well as without glucagon-like peptide 1 receptor agonists: a SMART-C collective meta-analysis of randomised regulated trials. Lancet Diabetes Mellitus Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Effects of tirzepatide versus blood insulin glargine on renal end results in type 2 diabetes mellitus in the SURPASS-4 trial: post-hoc evaluation of an open-label, randomised, phase 3 test.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K.
R. et al. Body weight as well as eGFR during the course of dulaglutide therapy in kind 2 diabetes mellitus and also moderate-to-severe persistent kidney condition (AWARD-7).
Diabetes mellitus Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J. L.
et al. Effects of tirzepatide versus blood insulin glargine on cystatin c-based renal feature: a SURPASS-4 post hoc review. Diabetes Care 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetes Mellitus Treatment (American Diabetic issues Association, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Impacts of bariatric surgical procedure on kidney functionality in overweight individuals: an organized review and also meta evaluation.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Bilha, S. C.
et al. The effects of bariatric surgery on kidney results: a systematic analysis and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et cetera. The determined glomerular purification rate (mGFR) prior to and also 6 months after bariatric surgery: a fly study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et cetera. Adiponectin reduces glomerular endothelial glycocalyx disruption and also brings back glomerular barricade feature in a computer mouse model of type 2 diabetes mellitus. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration pertaining to diabetes mellitus and also excessive weight in individual condition. Realm J.
Diabetes 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Determining albuminuria in individuals along with weight problems: difficulties of the urinary system albumin-creatinine ratio. Renal Medication.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in adults along with over weight or even obesity.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et al. An even more correct procedure to estimate glomerular filtering rate from serum creatinine: a new forecast formula.
Adjustment of Diet Regimen in Renal Condition Study Group. Ann. Trainee.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS strategy for iohexol judgment in human EDTA and also lithium-heparin blood, individual pee and also in goat- as well as porker EDTA plasma. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et cetera.
Efficacy and safety of aldosterone synthase restraint along with and also without empagliflozin for chronic kidney condition: a randomised, handled, phase 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et cetera. Efficiency of an unfamiliar inhibitor of general bond protein-1 in lessening albuminuria in individuals with diabetic person renal condition (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in clients along with chronic renal condition (ZENITH-CKD): a multicentre, randomised, active-controlled, stage 2b, professional trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Impact of avenciguat on albuminuria in people along with CKD: pair of randomized placebo-controlled tests.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in clients along with IgA nephropathy: a prespecified interim study due to a randomised, double-blind, active-controlled medical trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.